BRAIN Biotech

Main focus: Undisclosed

Company stage: Pre-clinical

Diseases (gene editing): Undisclosed

Genome editing tool: BRAIN-Engineered-Cas01 (BMC01) nuclease

Funding stage: Public (XETRA:BNN)

Location: Zwingenberg, Germany

Website: https://www.brain-biotech.com/

BRAIN Biotech is a company focused on providing solutions for industrial biotechnology. The company's engagement in the gene-editing space comes through its development of novel non-Cas9 nucleases that are being validated for gene editing in bacteria, fungi, yeast as well as in mammalian cells. While the company does not have any disclosed therapeutic programmes, the novel Cas systems may provide a way to expand into the therapeutic space.

BRAIN Biotech AG

Your Latest CMN News

Korro Bio to Begin RNA-Editing Trial in Alpha-1...

CMN Clinical

Dec. 4, 2024

Korro Bio has received clearance from the Australian regulatory body to initiate a Phase 1/2 trial of its RNA-editing therapeutic candiate KRRO-110 in...

Sound-Guided CRISPR: Ultrasound Unlocks Precision...

CMN Briefs

Dec. 3, 2024

Scientists engineered ultrasound-controlled CRISPR tools that can precisely edit genes deep within tissues, demonstrating successful gene regulation...

Multimodal Editing Maps Genetic Variants in EGFR

CMN Interview

Dec. 2, 2024

Researchers at ETH Zürich have introduced a combined base and prime editing approach to explore the mutational landscape of the epithelial growth...

CMN Weekly (29 November 2024) - Your Weekly CRISPR...

CMN Weekly

Nov. 29, 2024

Some of the best links we picked up around the internet

CARBON Newsletter (26 November 2024) - Your Latest...

Carbon

Nov. 26, 2024

Some of the best links we picked up around the internet